Back

Clinical impact of switching or continuation of apixaban or rivaroxaban among patients with non-valvular atrial fibrillation

25 August 2023 (07:30 - 18:30)
Organised by: Logo
Congress Presentation Part of: Oral anticoagulation in patients with atrial fibrillation Anticoagulants ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Steven Deitelzweig

Ochsner Medical Center, New Orleans (United States of America)

7 More presentations in this session

Presentation thumbnail
Ischemic and non-ischemic stroke reported in DOAC treated patients with atrial fibrillation and levetiracetam drug interaction: a real-world study
Doctor M. Abou Kaoud (Tel Aviv, IL)
Abstract Slides
Presentation thumbnail
Optimal adherence threshold to non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation to reduce the risk of thromboembolism and death
Mr M. Grymonprez (Gent, BE)
Abstract Slides Video
Presentation thumbnail
Risk and benefits of baseline antiplatelet therapy in 58,598 patients with atrial fibrillation randomized to NOACs vs warfarin
Doctor S. Patel (Boston, US)
Abstract Slides Video
Presentation thumbnail
Comparisons of effectiveness and safety between different dosage strategy in patients with atrial fibrillation treated with rivaroxaban: a systemic review and meta-analysis
Doctor T. Chao (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Comparison of baseline characteristics and outcomes of on-label full dose (20mg) and off-label reduced dose (15mg) rivaroxaban in patients with atrial fibrillation in Asian elderly patients
Doctor J. Kim (Seoul, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Oral anticoagulation in patients with atrial fibrillation

The Event

Event poster

ESC Congress 2023

25 August - 28 August 2023
You may be interested in
thumbnail
Congress Presentation
Effectiveness and safety of rivaroxaban vs apixaban in patients with Atrial Fibrillation and Peripheral Artery Disease
thumbnail
Congress Presentation
Switching from warfarin to a DOAC in frail elderly asian patients with atrial fibrillation: a nationwide population-based study
thumbnail
Congress Presentation
Risk and benefits of baseline antiplatelet therapy in 58,598 patients with atrial fibrillation randomized to NOACs vs warfarin

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources